Brief: Mesoblast Requests Modular Review Of BLA For Rexlemestrocel-L In End-Stage Heart Failure With LVAD
01/07/2026 02:32
BRIEF-Mesoblast Requests Modular Review Of BLA For Rexlemestrocel-L In End-Stage Heart Failure With LVAD July 1 (Reuters) - Mesoblast Ltd MSB.AX:
REQUESTS MODULAR REVIEW OF BLA FOR REXLEMESTROCEL-L IN END-STAGE HEART FAILURE WITH LVAD
REXLEMESTROCEL-L RECEIVES ORPHAN DRUG AND RMAT DESIGNATIONS
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil